Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSHA-107
- Development stage
- Preclinical
- Lead developer
- Taysha Gene Therapies
- Modality
- Gene Therapies
01
Overview
TSHA-107 is an experimental gene therapy developed for the treatment of an autism spectrum disorder. It is designed as a gene transfer drug, implying the use of gene therapy techniques to address pathological mechanisms underlying the disease. TSHA-107 was initially developed by The University of Texas Southwestern Medical Center. Detailed mechanism of action and targeted gene(s) have not been publicly disclosed, but TSHA-107 belongs to the class of gene therapies intended to introduce functional genetic material into cells to correct or mitigate disease processes[5][13].
- Brand names
- TSHA-107TSHA107TSHA 107
- Other names
- TSHA-107TSHA107TSHA 107
Beyond the preview
Go deeper on TSHA-107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSHA-107.